Literature DB >> 21185399

IL28B-genotype testing now and in the era of direct-acting antiviral agents.

Timothy R Morgan, Thomas R O'Brien.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21185399      PMCID： PMC3065520          DOI： 10.1016/j.cgh.2010.12.014

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  11 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

Review 2.  Genomic medicine--an updated primer.

Authors:  W Gregory Feero; Alan E Guttmacher; Francis S Collins
Journal:  N Engl J Med       Date:  2010-05-27       Impact factor: 91.245

3.  Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

Authors:  Albert Friedrich Stättermayer; Rudolf Stauber; Harald Hofer; Karoline Rutter; Sandra Beinhardt; Thomas Matthias Scherzer; Kerstin Zinober; Christian Datz; Andreas Maieron; Emina Dulic-Lakovic; Harald H Kessler; Petra Steindl-Munda; Michael Strasser; Christoph Krall; Peter Ferenci
Journal:  Clin Gastroenterol Hepatol       Date:  2010-08-20       Impact factor: 11.382

4.  Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.

Authors:  Jeanette J McCarthy; Josephine H Li; Alexander Thompson; Sunil Suchindran; Xiang Qian Lao; Keyur Patel; Hans L Tillmann; Andrew J Muir; John G McHutchison
Journal:  Gastroenterology       Date:  2010-02-19       Impact factor: 22.682

5.  Interferon-alfa, interferon-lambda and hepatitis C.

Authors:  Thomas R O'Brien
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

6.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Authors:  Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly
Journal:  Nat Immunol       Date:  2002-12-16       Impact factor: 25.606

7.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

8.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

9.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330
View more
  4 in total

Review 1.  Interferon-lambda and therapy for chronic hepatitis C virus infection.

Authors:  Raymond P Donnelly; Harold Dickensheets; Thomas R O'Brien
Journal:  Trends Immunol       Date:  2011-08-05       Impact factor: 16.687

2.  Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression.

Authors:  Pauline Ferraris; Partha K Chandra; Rajesh Panigrahi; Fatma Aboulnasr; Srinivas Chava; Ramazan Kurt; Jean-Michel Pawlotsky; Ludwig Wilkens; Pamela Osterlund; Rune Hartmann; Luis A Balart; Tong Wu; Srikanta Dash
Journal:  Am J Pathol       Date:  2016-02-16       Impact factor: 4.307

3.  IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.

Authors:  Barham K Abu Dayyeh; Namrata Gupta; Kenneth E Sherman; Paul I W de Bakker; Raymond T Chung
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

4.  IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.

Authors:  Fatma Aboulnasr; Sidhartha Hazari; Satyam Nayak; Partha K Chandra; Rajesh Panigrahi; Pauline Ferraris; Srinivas Chava; Ramazan Kurt; Kyongsub Song; Asha Dash; Luis A Balart; Robert F Garry; Tong Wu; Srikanta Dash
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.